BioSpace News Archive

Primmune Therapeutics today presented clinical data from its first-in-human, Phase 1 study of PRTX007, an orally administered prodrug of a novel, small molecule toll-like receptor 7 (TLR7)-specific agonist, at the 2023 American Association for the Study of Liver Diseases (AASLD) Annual Meeting (The Liver Meeting).

Sosei Group Corporation announced the successful identification, validation and nomination of a first G protein-coupled receptor target to enter a therapeutic discovery program for gastrointestinal diseases.

IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced that the Company will present two posters at the Society for Neuro-Oncology (SNO) 28th Annual Meeting, taking place November 15-19, 2023, in Vancouver, British Columbia.

Seegene Inc. announced on November 10 that it has received an overall rating of ‘B+' in the 2023 ESG evaluation conducted by the Korea Institute of Corporate Governance and Sustainability.

Madrigal Pharmaceuticals, Inc. today announced that Carole Huntsman has been appointed Chief Commercial Officer.

Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, announced today its results for the quarter ended September 30, 2023 and provided a corporate update.

Ocugen, Inc. today announced that the first patient has been dosed in its Phase 1/2 GARDian clinical trial for OCU410ST (AAV5- hRORA ).

Merck Receives Positive EU CHMP Opinion for KEYTRUDA ® (pembrolizumab) Plus Gemcitabine and Cisplatin as First-Line Treatment for Locally Advanced Unresectable or Metastatic Biliary Tract Cancer.

KDx Diagnostics, a pioneering medical device company known for its innovative noninvasive urine test for bladder cancer, the URO17Ò test, is thrilled to announce strategic partnerships with leading distributors in Europe.

Integrum announces that the US Department of Defense has decided to fully fund a clinical study of OPRA™ Implant System on up to 30 patients with transtibial amputations.